Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jorge Suarez

Gastroenterology Doral, FL Medical Doctor

NPI 1356617351 CMS profile 1399226

10305 Nw 41St Street, Suite 212, Doral, FL 33178

Open in the dashboard

General payments

$11,782

427 records reported · program years 2019–2025

Research payments

$10,920

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$70 paid to institutions, not to them · program year 2022

Through program year 2025, Jorge Suarez of Doral, FL is reported in the CMS Open Payments database as having received $11,782 across 427 general payments and $10,920 in research payments paid to them. Separately, studies naming them as principal investigator received $70 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,568 81
2024 General $3,283 99
2023 General $1,599 74
2022 General $1,934 78
2022 Research $10,920 2
2021 General $1,832 81
2020 General $399 10
2019 General $167 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jorge Suarez
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Jorge Suarez were reported at $2,568. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Jorge Suarez Gastroenterology median Middle half National median
2019 $167 $417 $126–$1,100 $163
2020 $399 $224 $74–$624 $114
2021 $1,832 $352 $106–$1,054 $132
2022 $1,934 $448 $129–$1,270 $149
2023 $1,599 $533 $150–$1,390 $160
2024 $3,283 $605 $160–$1,606 $164
2025 $2,568 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $1,810 74 payments
  2. CONMED Corporation $1,105 12 payments
  3. Genzyme Corporation $879 30 payments
  4. QOL Medical, LLC $859 49 payments
  5. AbbVie, Inc. $853 37 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $672 52 payments
  7. Phathom Pharmaceuticals, Inc. $488 17 payments
  8. Ardelyx, Inc. $400 24 payments
  9. E.R. Squibb & Sons, L.L.C. $387 3 payments
  10. FUJIFILM Medical Systems USA, Inc. $345 3 payments
  11. Other $3,984 126 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,398 421 payments
  2. Education $384 6 payments
Products named General payments · program years 2019–2025
  1. STELARA $1,371 53 payments
  2. CONMED BILIARY $935 8 payments
  3. TREMFYA $885 25 payments
  4. DUPIXENT $879 30 payments
  5. CONMED GENERATORS $786 6 payments
  6. CONMED HEMOSTASIS $657 6 payments
  7. ZEPOSIA $579 13 payments
  8. XIFAXAN $554 41 payments
  9. IBSRELA $400 24 payments
  10. Sucraid $395 22 payments
  11. Other $6,656 249 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $10,920 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

618

Median for Gastroenterology: 569

Drug cost

$144,845

Median for Gastroenterology: $104,976

Branded share of claims

81.4%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zenpep Lipase/Protease/Amylase Brand 28 $93,872
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 126 $21,609
Linzess Linaclotide Brand 32 $17,197
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 55 $3,544
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 21 $3,440
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 132 $2,630
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 40 $654
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 40 $597
Omeprazole Generic 46 $493
Pantoprazole Sodium Generic 56 $345

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$69,366

Medicare's payments for the services billed

Medicare patients

220

Average age 75

Services billed

707

132 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 52%
Arthritis 49%
Depression 44%
Ischemic heart disease 41%
Chronic kidney disease 41%
Heart failure 40%
COPD 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
STELARA
  • Janssen Biotech, Inc. $319
$319 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $296
$296 — —
DUPIXENT
  • GENZYME CORPORATION $277
  • Regeneron Healthcare Solutions, Inc. $16
$294 — —
Sucraid
  • QOL Medical, LLC $270
$270 — —
TREMFYA
  • Janssen Biotech, Inc. $177
$177 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

429 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record